More CLEO Diagnostics Ltd news
CLEO Diagnostics LtdASX: COV

CLEO Selects U.S. Clinical Trial Sites

Jul 30, 2024 at 10:44 PM EDT · Issued by CLEO Diagnostics Ltd

Filed with ASX · Jul 30, 2024 at 10:44 PM EDT

On 6ix: 6ix.com/news/cleo-selects-us-clinical-trial-sites

Cleo Diagnostics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

CLEO Diagnostics Ltd on 6ix

Earlier from CLEO Diagnostics

  • Cleo Commences US Regulatory Process with FDAJun 25, 2024
  • COV Ovarian Cancer Blood Test Outperforms Clinical BenchmarkMay 28, 2024
  • COV Appoints CRO to Manage US Ovarian Cancer Clinical TrialsApr 10, 2024
  • CLEO Appoints Partner to Commence U.S. Market Access ProgramApr 2, 2024
  • Peer-Review Supports CLEOs Ovarian Cancer Detection TechMar 24, 2024

Later from CLEO Diagnostics

  • Appendix 4E and 2024 Annual ReportAug 27, 2024
  • Cleo Commences U.S. Clinical TrialsSep 5, 2024
  • The Royal Women's Hospital Joins CLEO Ovarian Cancer TrialNov 26, 2024
  • CLEO Further Expands Ovarian Cancer Trial with Siles HealthDec 9, 2024
  • Price Query ResponseFeb 7, 2025
All CLEO Diagnostics news releases↗

Follow CLEO Diagnostics into a list and get an email when it puts out news.

Follow CLEO Diagnostics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer